Recombinant lactic acid bacteria as mucosal biotherapeutic agents

Trends in Biotechnology

Volumn 29, Issue 10, 2011, Pages 499-508

  Daniel, Catherine ^a   Roussel, Yvonne ^b   Kleerebezem, Michiel ^c,d   Pot, Bruno ^a  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c NIZO FOOD RESEARCH   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; CLINICAL TRIAL; GASTROINTESTINAL TRACT; GI TRACT; HEALTH BENEFITS; HUMAN HEALTH; IN-SITU; LACTIC ACID BACTERIA; SAFETY STATUS; THERAPEUTIC PROTEIN; THERAPEUTIC TOOLS;

BACTERIA; PROTEINS;

LACTIC ACID;

IMMUNOGLOBULIN A;

ALLERGY; ENTERITIS; GASTROINTESTINAL TRACT; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTESTINE MUCOSA; LACTIC ACID BACTERIUM; LACTOBACILLUS JOHNSONII; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADMINISTRATION, MUCOSAL; ANIMALS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL DISEASES; GENETIC ENGINEERING; HUMANS; INTESTINAL MUCOSA; LACTOBACILLALES; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 80052820596     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2011.05.002     Document Type: Review

References (80)

1. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 2008, 6:349-362.
2. Berlec A., Strukelj B. Novel applications of recombinant lactic acid bacteria in therapy and in metabolic engineering. Recent Pat. Biotechnol. 2009, 3:77-87.
3. Villatoro-Hernandez J., et al. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation. Exp. Opin. Biol. Ther. 2011, 11:261-267.
4. Mohamadzadeh M., et al. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4331-4336.
5. Foligne B., et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007, 133:862-874.
6. Schwarzer M., et al. Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. Allergy 2011, 66:368-375.
7. Cheung Q.C., et al. Generation of epidermal growth factor-expressing Lactococcus lactis and its enhancement on intestinal development and growth of early-weaned mice. Am. J. Clin. Nutr. 2009, 89:871-879.
8. Robinson K., et al. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 1997, 15:653-657.
9. Bahey-El-Din M., et al. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model. Vaccine 2008, 26:5304-5314.
10. Daniel C., et al. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine 2009, 27:1141-1144.
11. Lee M.H., et al. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19:3927-3935.
12. Cortes-Perez N.G., et al. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007, 25:6581-6588.
13. Mohamadzadeh M., et al. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future Microbiol. 2010, 5:1289-1296.
14. Schabussova I., Wiedermann U. Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr. Opin. Allergy Clin. Immunol. 2008, 8:557-564.
15. Kruisselbrink A., et al. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin. Exp. Immunol. 2001, 126:2-8.
16. Adel-Patient K., et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin. Exp. Allergy 2005, 35:539-546.
17. Rigaux P., et al. Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy. Allergy 2009, 64:406-414.
18. Daniel C., et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 2006, 61:812-819.
19. Huibregtse I.L., et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007, 133:517-528.
20. Huibregtse I.L., et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J. Immunol. 2009, 183:2390-2396.
21. Frossard C.P., et al. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J. Allergy Clin. Immunol. 2007, 119:952-959.
22. Hazebrouck S., et al. Influence of the route of administration on immunomodulatory properties of bovine beta-lactoglobulin-producing Lactobacillus casei. Vaccine 2009, 27:5800-5805.
23. Steidler L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
24. Braat H., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4:754-759.
25. Vandenbroucke K., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004, 127:502-513.
26. Caluwaerts S., et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010, 46:564-570.
27. Carroll I.M., et al. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G729-G738.
28. Watterlot L., et al. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int. J. Food Microbiol. 2010, 144:35-41.
29. Rochat T., et al. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb. Cell Fact. 2007, 6:22.
30. Vandenbroucke K., et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010, 3:49-56.
31. Ravnikar M., et al. Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha. Appl. Environ. Microbiol. 2010, 76:6928-6932.
32. Wall T., et al. The early response to acid shock in Lactobacillus reuteri involves the ClpL chaperone and a putative cell wall-altering esterase. Appl. Environ. Microbiol. 2007, 73:3924-3935.
33. Pfeiler E.A., et al. Characterization of a novel bile-inducible operon encoding a two-component regulatory system in Lactobacillus acidophilus. J. Bacteriol. 2007, 189:4624-4634.
34. de Vos W.M., et al. Post-genomics of lactic acid bacteria and other food-grade bacteria to discover gut functionality. Curr. Opin. Biotechnol. 2004, 15:86-93.
35. Bron P.A., et al. Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice. J. Bacteriol. 2004, 186:5721-5729.
36. Denou E., et al. Gene expression of commensal Lactobacillus johnsonii strain NCC533 during in vitro growth and in the murine gut. J. Bacteriol. 2007, 189:8109-8119.
37. Marco M.L., et al. Lifestyle of Lactobacillus plantarum in the mouse caecum. Environ. Microbiol. 2009, 11:2747-2757.
38. Marco M.L., et al. Convergence in probiotic Lactobacillus gut-adaptive responses in humans and mice. ISME J. 2010, 4:1481-1484.
39. Beganovic J., et al. Characterization of the insoluble proteome of Lactococcus lactis by SDS-PAGE LC-MS/MS leads to the identification of new markers of adaptation of the bacteria to the mouse digestive tract. J. Proteome Res. 2010, 9:677-688.
40. Borchers A.T., et al. Probiotics and immunity. J. Gastroenterol. 2009, 44:26-46.
41. Foligne B., et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterol. 2007, 13:236-243.
42. Karczewski J., et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G851-G859.
43. Kwon H.K., et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2159-2164.
44. Kleerebezem M., et al. The extracellular biology of the lactobacilli. FEMS Microbiol. Rev. 2010, 34:199-230.
45. Konstantinov S.R., et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19474-19479.
46. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 2008, 36:1478-1481.
47. Meijerink M., et al. Identification of genetic loci in Lactobacillus plantarum that modulate the immune response of dendritic cells using comparative genome hybridization. PLoS ONE 2010, 5:e10632.
48. van Hemert S., et al. Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol. 2010, 10:293.
49. McFarland A.P., et al. Localized delivery of interferon-beta by Lactobacillus exacerbates experimental colitis. PLoS ONE 2011, 6:e16967.
50. van Baarlen P., et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2371-2376.
51. van Baarlen P., et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 1):4562-4569.
52. Waeytens A., et al. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflamm. Bowel Dis. 2008, 14:471-479.
53. Morello E., et al. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. J. Mol. Microbiol. Biotechnol. 2008, 14:48-58.
54. Marco M.L., et al. Spatial and temporal expression of Lactobacillus plantarum genes in the gastrointestinal tracts of mice. Appl. Environ. Microbiol. 2007, 73:124-132.
55. Driessen A.J., Nouwen N. Protein translocation across the bacterial cytoplasmic membrane. Annu. Rev. Biochem. 2008, 77:643-667.
56. Welch M., et al. Design parameters to control synthetic gene expression in Escherichia coli. PLoS ONE 2009, 4:e7002.
57. Daniel C., et al. The European LABDEL project and its relevance to the prevention and treatment of allergies. Allergy 2007, 62:1237-1242.
58. Fernandez A., et al. Enhanced secretion of biologically active murine interleukin-12 by Lactococcus lactis. Appl. Environ. Microbiol. 2009, 75:869-871.
59. Mathiesen G., et al. Genome-wide analysis of signal peptide functionality in Lactobacillus plantarum WCFS1. BMC Genomics 2009, 10:425.
60. Berlec A., et al. Identification of candidate carrier proteins for surface display on Lactococcus lactis by theoretical and experimental analyses of the surface proteome. Appl. Environ. Microbiol. 2011, 77:1292-1300.
61. Martin M.C., et al. Integrative expression system for delivery of antibody fragments by lactobacilli. Appl. Environ. Microbiol. 2011, 77:2174-2179.
62. Quigley B.R., et al. A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity. Infect. Immun. 2010, 78:1294-1303.
63. Nouaille S., et al. Influence of lipoteichoic acid D-alanylation on protein secretion in Lactococcus lactis as revealed by random mutagenesis. Appl. Environ. Microbiol. 2004, 70:1600-1607.
64. Stentz R., et al. Controlled release of protein from viable Lactococcus lactis cells. Appl. Environ. Microbiol. 2010, 76:3026-3031.
65. Buist G., et al. Autolysis of Lactococcus lactis caused by induced overproduction of its major autolysin, AcmA. Appl. Environ. Microbiol. 1997, 63:2722-2728.
66. de Ruyter P.G., et al. Food-grade controlled lysis of Lactococcus lactis for accelerated cheese ripening. Nat. Biotechnol. 1997, 15:976-979.
67. Dieye Y., et al. Functionality of sortase A in Lactococcus lactis. Appl. Environ. Microbiol. 2010, 76:7332-7337.
68. Sriraman K., Jayaraman G. HtrA is essential for efficient secretion of recombinant proteins by Lactococcus lactis. Appl. Environ. Microbiol. 2008, 74:7442-7446.
69. Marreddy R.K., et al. Amino acid accumulation limits the overexpression of proteins in Lactococcus lactis. PLoS ONE 2010, 5:e10317.
70. Steidler L., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 2003, 21:785-789.
71. Shkoporov A.N., et al. Characterization of plasmids from human infant Bifidobacterium strains: sequence analysis and construction of E. coli-Bifidobacterium shuttle vectors. Plasmid 2008, 60:136-148.
72. Cronin M., et al. Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. BMC Microbiol. 2008, 8:161.
73. Cronin M., et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol. Ther. 2010, 18:1397-1407.
74. Yamamoto S., et al. Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 2010, 28:6684-6691.
75. Fredriksen L., et al. Cell wall anchoring of the 37-kilodalton oncofetal antigen by Lactobacillus plantarum for mucosal cancer vaccine delivery. Appl. Environ. Microbiol. 2010, 76:7359-7362.
76. Bermudez-Humaran L.G., et al. Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl. Environ. Microbiol. 2007, 73:5300-5307.
77. Rosberg-Cody E., et al. Recombinant lactobacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. Microbiology 2011, 157:609-615.
78. Chatel J.M., et al. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther. 2008, 15:1184-1190.
79. Innocentin S., et al. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl. Environ. Microbiol. 2009, 75:4870-4878.
80. Nicaise C., et al. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology 2008, 48:1184-1192.